Business Wire

Amadis and WorldLine Rollout Global Payment Solution with Subway® Restaurants

23.2.2021 13:00:00 EET | Business Wire | Press release

Share

WorldLine, the European market leader in payment and transaction services, and Amadis today announced the completion of its multi-country payment solution rollout with Subway® restaurants. Together WorldLine, Amadis and Subway executed a payments solution to streamline its global payment infrastructure and provide secure, cost-effective and optimized operations for Franchisees.

Subway Franchisees independently own and operate more than 40,000 restaurants in over 100 countries. The use of this new universal payment software makes it easier to operate Subway’s previous international payment infrastructure and provides restaurant owners with a consistent and reliable payment acceptance user-experience. The new framework also allows for a faster deployment of new payment solutions on a global scale, with a projected reduction of testing and certification costs.

“Amadis provided us with clear, proven expertise, ensuring the successful rollout of this global payments project with WorldLine,” said Benoit Lamoureux, payment product owner of Subway® restaurants. “With its unique global perspective in payment software editing, development and standards, along with its reputation for elite global payment deployments, Amadis provided us with assurance that we were addressing key technical issues while implementing this mission-critical initiative.”

“We are pleased to be Subway’s preferred provider of Omni-Channel Payment Solutions,” said Guillaume Pascal, Head of GSV Go To Market / Merchant Services. “WorldLine’s solutions include point of sale system (POS) and e-commerce acceptance as well as payment terminals operating with the nexo retail protocol. An entirely new level of flexibility and efficiency is enabled by implementing the nexo retail protocol and universal payment software that facilitates the connection between card payment infrastructure and the retail POS system.”

“As an expert in global payment standards as well as payment software development, we understand the myriad of system integration and operational issues involved to make large scale, international payment deployments a success,” said Emmanuel Haydont, CEO and co-founder of Amadis. “Global merchants, such as Subway, can realize tremendous efficiencies and cost-savings through global standards and a unified payment framework, while enabling a new level of innovation.”

ABOUT SUBWAY® RESTAURANTS

The Subway restaurant chain continues to evolve the dining experience, offering guests in more than 100 countries quality ingredients and robust flavor combinations with nearly 7 million made-to-order sandwiches created each day. As a Quick Service Restaurant, Subway provides a fresh alternative to traditional fast food offering billions of sandwiches, salad and wrap combinations to guests each day. All approximately 42.500 Subway restaurants are owned and operated by almost 21,000 Franchise Owners who employ hundreds of thousand people around the world, making Subway the world’s largest small business network.

The Subway experience is also delivered online at Subway.com and with the Subcard app.

Subway® is a Registered Trademark of Subway IP LLC. © 2021 Subway IP LLC.

About Worldline

Worldline [Euronext: WLN] is the European leader in the payments and transactional services industry and #4 player worldwide. With its global reach and its commitment to innovation, Worldline is the technology partner of choice for merchants, banks and third-party acquirers as well as public transport operators, government agencies and industrial companies in all sectors. Powered by over 20,000 employees in more than 50 countries, Worldline provides its clients with sustainable, trusted and secure solutions across the payment value chain, fostering their business growth wherever they are. Services offered by Worldline in the areas of Merchant Services; Terminals, Solutions & Services; Financial Services and Mobility & e-Transactional Services include domestic and cross-border commercial acquiring, both in-store and online, highly-secure payment transaction processing, a broad portfolio of payment terminals as well as e-ticketing and digital services in the industrial environment. In 2019 Worldline generated a proforma revenue of 5.3 billion euros. worldline.com

ABOUT AMADIS

Amadis is a privately-held division of Maxim Integrated. Amadis is a leader in payment software technology, with its software running on more than 10 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment processing options using custom or commercially available technology, independent of hardware or geography. The company brings an elite, experienced software team to the industry and enables solutions for international merchants in over 23 countries. Learn more at www.amadis.ca.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Vivian Shen
+1 437-232-7968
vsh@amadis.ca

Susanne Stöger
+43 1 71701 6524
susanne.stoeger@worldline.com

Hélène Carlander
+33 (0)7 72 25 96 04
helene.carlander@ingenico.com

Ashley Laryea
press@subway.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye